Carisma Therapeutics IncNASDAQ:CARMNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.1000
- TODAY'S CHANGE (%)0.0500 (4.7619%)
- Bid / Lots1.0900/ 13
- Ask / Lots1.1000/ 95
- Open / Previous Close1.0700 / 1.0500
- Day Range
- 52 Week Range
- Volume85,299
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CARM |
|---|---|---|
| 09:32 ET | 6851 | 1.05 |
| 09:33 ET | 100 | 1.0599 |
| 09:35 ET | 100 | 1.055 |
| 09:37 ET | 399 | 1.0501 |
| 09:42 ET | 10697 | 1.08 |
| 09:44 ET | 3988 | 1.0996 |
| 09:46 ET | 2800 | 1.08 |
| 09:48 ET | 107 | 1.085 |
| 09:50 ET | 7932 | 1.0802 |
| 09:51 ET | 200 | 1.0807 |
| 09:55 ET | 2600 | 1.09 |
| 09:57 ET | 8050 | 1.095 |
| 10:00 ET | 3048 | 1.085 |
| 10:02 ET | 1300 | 1.075 |
| 10:04 ET | 1980 | 1.075 |
| 10:06 ET | 900 | 1.085 |
| 10:08 ET | 6235 | 1.09 |
| 10:11 ET | 800 | 1.09 |
| 10:13 ET | 2460 | 1.0801 |
| 10:20 ET | 800 | 1.09 |
| 10:22 ET | 1504 | 1.0806 |
| 10:26 ET | 700 | 1.09 |
| 10:29 ET | 1269 | 1.0901 |
| 10:31 ET | 740 | 1.0975 |
| 10:33 ET | 1400 | 1.09 |
| 10:36 ET | 725 | 1.0906 |
| 10:40 ET | 600 | 1.09 |
| 10:42 ET | 611 | 1.09 |
| 10:44 ET | 4965 | 1.09 |
| 10:45 ET | 100 | 1.09 |
| 10:47 ET | 100 | 1.09 |
| 10:49 ET | 1050 | 1.095 |
| 10:54 ET | 100 | 1.095 |
| 10:58 ET | 300 | 1.095 |
| 11:00 ET | 100 | 1.0925 |
| 11:02 ET | 1568 | 1.0934 |
| 11:05 ET | 600 | 1.1 |
Today
Oct 30, 2024
Press Release: Carisma Therapeutics Announces Changes to its Board of Directors, from 4:30PM ET on Wednesday Oct 30, 2024 by Dow Jones
4:30PM ET on Wednesday Oct 30, 2024 by Dow JonesCarisma Therapeutics Announces Changes to its Board of Directors, from 4:30PM ET on Wednesday Oct 30, 2024 by Dow Jones
4:30PM ET on Wednesday Oct 30, 2024 by Dow JonesDJ Carisma Therapeutics Initiated at Buy by EF Hutton, from 9:26AM ET on Wednesday Oct 30, 2024 by Dow Jones
9:26AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Carisma Therapeutics Inc | 43.6M | -0.6x | --- |
Aligos Therapeutics Inc | 30.3M | -0.4x | --- |
Collplant Biotechnologies Ltd | 42.5M | -2.4x | --- |
ImmuCell Corp | 28.1M | -7.0x | --- |
HOOKIPA Pharma Inc | 45.3M | -0.7x | --- |
Curis Inc | 36.0M | -0.5x | --- |
Company Information
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Contact Information
- Headquarters
- 245 1st St Ste 1800CAMBRIDGE, MA, United States 02142-1292
- Phone
- 617-444-8550
- Fax
- 617-858-0911
Executives
- Independent Non-Executive Chairman of the Board
- Sanford Zweifach
- President, Chief Executive Officer, Director
- Steven Kelly
- Chief Financial Officer
- Richard Morris
- Chief Scientific Officer
- Michael Klichinsky
- General Counsel, Corporate Secretary
- Eric Siegel
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $43.6M |
|---|---|
Revenue (TTM) | $20.7M |
Shares Outstanding | 41.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.54 |
EPS | $-1.78 |
Book Value | $0.65 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -366.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
